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ORIGINAL RESEARCH
Clinically Meaningful Change in Quality of 
Life and Associated Factors Among Older 
Patients With Atrial Fibrillation
Hawa O. Abu , MD, PhD, MPH; Jane S. Saczynski, PhD; Jordy Mehawej, MD; Mayra Tisminetzky, MD, PhD, MPH; 
Catarina I. Kiefe, MD, PhD; Robert J. Goldberg , PhD; David D. McManus, MD, ScM
BACKGROUND: Among older patients with atrial fibrillation, there are limited data examining clinically meaningful changes in 
quality of life (QoL). We examined the extent of, and factors associated with, clinically meaningful change in QoL over 1-year 
among older adults with atrial fibrillation.
METHODS AND RESULTS: Patients from cardiology, electrophysiology, and primary care clinics in Massachusetts and Georgia 
were enrolled in a cohort study (2015–2018). The Atrial Fibrillation Effect on Quality-of-Life questionnaire was used to as-
sess overall QoL and across 3 subscales: symptoms, daily activities, and treatment concern. Clinically meaningful change in 
QoL (ie, difference between 1-year and baseline QoL score) was categorized as either a decline (≤−5.0 points), no clinically 
meaningful change (−5.0 to +5.0 points), or an increase (≥+5.0 points). Ordinal logistic models were used to examine fac-
tors associated with QoL changes. Participants (n=1097) were on average 75 years old, 48% were women, and 87% White. 
Approximately 40% experienced a clinically meaningful increase in QoL and 1 in every 5 patients experienced a decline in 
QoL. After multivariable adjustment, women, non-Whites, those who reported depressive and anxiety symptoms, fair/poor 
self-rated health, low social support, heart failure, or diabetes mellitus experienced clinically meaningful declines in QoL.
CONCLUSIONS: These findings provide insights to the magnitude of, and factors associated with, clinically meaningful change 
in QoL among older patients with atrial fibrillation. Assessment of comorbidities and psychosocial factors may help identify 
patients at high risk for declining QoL and those who require additional surveillance to maximize important clinical and patient-
centered outcomes.
Key Words: atrial fibrillation ■ elderly ■ quality of life
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia worldwide and has often been asso-ciated with impaired quality of life (QoL).1,2 The 
onset of AF symptoms including palpitations, fatigue, 
chest pain, and dyspnea, and the consequences of 
AF treatment, such as medication side effects as well 
as frequent hospitalizations, could negatively impact 
patients’ QoL.3,4 Consequently, one of the primary ob-
jectives in AF management is to alleviate patients’ suf-
fering or discomfort through rate or rhythm control with 
the goal of improving their functional status and QoL.5 
Understanding the factors that may influence clinically 
meaningful changes in QoL is important in the delivery 
of patient-centered care and to improve the long-term 
health outcomes in older patients with AF and other 
chronic diseases.
Although previous cross-sectional studies have ex-
amined generic and disease-specific QoL in patients 
with AF,6–8 only limited research has prospectively 
examined changes in QoL over time reporting find-
ings based on statistical, rather than clinically signif-
icant changes in QoL, thus lacking clinical relevance 
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or implication on patient’s long-term clinical course 
and health outcomes.9,10 Because of the intrinsically 
subjective nature of patient reported outcomes such 
as QoL, there is no gold standard for defining clini-
cally meaningful change in QoL.11 Still, a few studies 
among patients with AF have suggested approaches 
that could be used for defining clinically meaningful 
change in QoL based on patient reported magnitude 
of change in their QoL.12,13 Yet, no prior studies have 
examined the extent of clinically meaningful change in 
QoL, and patient and clinical factors that are associ-
ated with clinically meaningful change in QoL among 
older patients with AF.
Using data from the prospective multi-center 
study, SAGE-AF (Systematic Assessment of Geriatric 
Elements in Atrial Fibrillation), we examined clinically 
meaningful changes in QoL over a 1 year follow-up pe-
riod in patients aged ≥65 years with AF and examined 
a variety of patient sociodemographic, psychosocial, 
and clinical factors associated with clinically meaning-
ful change in QoL among these patients.
METHODS
The data, analytic methods, and study materials will be 
made available to other researchers upon reasonable 
request made to the SAGE-AF study principal investi-
gators (J.S., D.M.).
Study Population
The present study used data from an ongoing pro-
spective study: SAGE-AF.14,15 Between 2015 and 2018, 
patients were recruited from 1 of 4 clinical sites in 
Central Massachusetts (University of Massachusetts 
Memorial Health Care internal medicine, cardiology, 
electrophysiology, or Heart Rhythm Associates of 
Central MA), 1 clinical site in Eastern Massachusetts 
(Boston University cardiology), or 1 of 2 practices in 
Central Georgia (Family Health Center and Georgia 
Arrhythmia Consultants). Eligible participants were (1) 
aged ≥65 years; (2) diagnosed with AF if this arrhythmia 
was detected on Holter monitor, electrocardiography 
tracings, or was documented in any clinic or hospital 
record; and (3) had a CHA2DS2-VASC risk score ≥2. 
Patients were ineligible for study enrollment if they had 
documentation of an absolute contraindication to the 
use of oral anticoagulants, or an indication for oral an-
ticoagulation other than AF (ie, mechanical heart valve, 
deep venous thrombosis, or pulmonary embolism); if 
they were unable to provide signed informed consent; 
did not speak English; were scheduled for an inva-
sive procedure with high risk for uncontrolled bleed-
ing; if they were pregnant; were incarcerated; or if they 
were unwilling or unable to attend scheduled 1- and 
2-year study follow-up visits. Of the 6507 individuals 
screened, a total of 1244 participants were enrolled in 
this prospective study and completed their baseline 
examination (Figure).
Trained research personnel abstracted data from 
hospital medical records and conducted face-to-face 
or telephone interviews with each participant at base-
line, and 1 and 2 years of follow-up. The Institutional 
Review Boards at the University of Massachusetts 
Medical School, Boston University, and Mercer 
University approved this investigation. Each eligible 
participant provided written informed consent before 
formal study enrollment.
Assessment of QoL
At the time of study enrollment and at 1  year of 
follow-up, we assessed participants’ QoL using 
the Atrial Fibrillation Effect Quality-of-Life (AFEQT) 
Questionnaire.16 This 20-item questionnaire is a vali-
dated and reliable disease specific measure that asks 
participants to self-report the extent to which their 
experience of AF may have affected their QoL in the 
prior 4 weeks with 7 response options in a Likert scale 
CLINICAL PERSPECTIVE
What Is New?
• We observed that 1 in 5 older adults with atrial 
fibrillation had clinically meaningful decline in 
quality of life over 1-year.
• Clinically meaningful decline in quality of life was 
associated with sex, symptoms of depression, 
anxiety, fair/poor self-rated health, lower social 
support, previously diagnosed comorbidities, 
and polypharmacy.
What Are the Clinical Implications?
• Prompt recognition and addressing the poor 
psychosocial factors and comorbidities in older 
adults with atrial fibrillation may potentially im-
prove patient-centered outcomes, including 
quality of life.
Nonstandard Abbreviations and Acronyms
AF atrial fibrillation
AFEQT Atrial Fibrillation Effect on 
Quality-of-Life
ORBIT-AF Outcomes Registry for Better Informed 
Treatment of Atrial Fibrillation
QoL quality of life
SAGE-AF Systematic Assessment of Geriatric 
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that include: “Not at all bothered Or I did not have 
this symptom”, “Hardly bothered”, “A little bothered”, 
“Moderately bothered”, “Quite a bit bothered”, “Very 
bothered”, and “Extremely bothered”. Based on the 
developers’ guidelines, the overall AFEQT summary 
score was derived from summing up responses to 
the 18 items belonging to 3 subscales: symptoms (4 
items), daily activities (8 items), and treatment concerns 
(6 items) subscale, with a total score ranging from 0 to 
100 with higher scores indicating better QoL. In addi-
tion, each subscale, namely symptoms, daily activities, 
and the treatment concern subscale was scored sepa-
rately with scores ranging from 0 (worst QoL score) 
to 100 (best QoL score). The symptoms subscale as-
sessed the extent to which patients’ physical symp-
toms (palpitations, light headedness, or dizziness) may 
have been bothersome to them in the prior 4 weeks. 
The daily activities subscale measured the extent of 
difficulty patients experienced in carrying out their reg-
ular physical activities, exercising, walking briskly, or 
doing vigorous activities. The treatment concern sub-
scale assessed whether patients were worried or anx-
ious that there AF could begin at any time or worsen 
their coexisting medical conditions. The Treatment sat-
isfaction subscale (2-items) scores were not included 
in the overall AFEQT summary score.16
A difference of at least 5 points between the base-
line and 1-year AFEQT overall score and for each sub-
scale was considered a clinically meaningful difference 
based on recent reports by the AFEQT developers 
using data from the ORBIT-AF (Outcomes Registry 
for Better Informed Treatment of Atrial Fibrillation) 
registry.13 We categorized patients into the following 
3 groups: (1) clinically meaningful decline in QoL (1-
year QoL score—Baseline QoL score ≤−5.0 points); 
(2) no clinically meaningful change in QoL (1-year QoL 
score—Baseline QoL score between −5.0 to +5.0 
points); and (3) clinically meaningful increase in QoL 
(1-year QoL score—Baseline QoL score ≥+5.0 points.
Baseline Participant Characteristics
Participant sociodemographic data including meas-
ures of age and sex were derived from the review 
of electronic medical records. Other sociodemo-
graphic characteristics such as race/ethnicity, 
marital status, and highest level of education were 
obtained during the baseline face-to-face or tel-
ephone interviews. Clinical measures assessed 
from medical records included type of AF (parox-
ysmal, persistent, and permanent), time since AF 
diagnosis, receipt of rate or rhythm control therapy, 
previously diagnosed comorbidities including hy-
pertension, dyslipidemia, diabetes mellitus, heart 
failure, arthritis, anemia, and cancer, polypharmacy 
(receipt of ≥5 medications). Calculated risk scores 
including CHA2DS2-VASc, HASBLED, and Charlson 
Comorbidity index were derived from patient’s rel-
evant medical history.17,18 Psychosocial and geriat-
ric elements were obtained from comprehensive 
Figure. Baseline SAGE-AF study enrollment flowchart, 2016 to 2018.
AF indicates atrial fibrillation; and SAGE-AF, Systematic Assessment of 
Geriatric Elements in Atrial Fibrillation.
Total Paents Screened 






Reasons for Ineligibility 
Not English speaking (n=857) 
Absolute or relave contraindicaon 
to ancoagulaon (n=695) 
Unable to provide consent (n=275) 
Watchman device for stroke 
prevenon (n=121) 
Indicaon for ancoagulaon other 
than AF (n=108) 
Planned to move within 2 years 
(n=31) 





Reasons paents were not enrolled 
No, but maybe next visit (n=1054) 
Not interested (n=753) 
Not approached due to me 
constraints (n=657) 
Cancel/no show (n=505) 
Provider indicated candidate not fit 
(n=111) 
Family did not want paent to be 
involved in research (n=14) 
Time required is too much (n=13) 
Not feeling well at me of consent 
(n=7) 
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structured interviews including measures of social 
support, cognitive impairment, frailty, symptoms of 
depression and anxiety, independent functioning, 
hearing and visual impairment, self-rated health, and 
history of falls. Social support was assessed with the 
5-items Medical Outcomes Social Support Survey 
Instrument.19 Cognitive impairment was assessed 
using the 30-item Montreal Cognitive Assessment 
Battery with scores ranging 0 to 30 (higher scores 
indicative of better cognitive functioning) and a cut-
off of ≤23 suggestive of cognitive impairment.20,21 
Frailty was assessed by the Cardiovascular Health 
Survey frailty scale (0: not frail, 1–2: pre-frail, and 
≥3: frail).22 Symptoms of depression were measured 
with the 9-item Patient Health Questionnaire (≤4: no 
depressive symptom, 5–9: mild, ≥10: moderate to 
severe depressive symptoms).23 Anxiety symptoms 
were assessed with the 7-item Generalized Anxiety 
Disorder questionnaire (no anxiety symptom [≤4], 
mild [5–9], moderate to severe [≥10] anxiety symp-
toms).24 Level of independence was examined with 
the instrumental activities of daily living including 
basic communication skills, transportation, meal 
preparation, shopping, housework, managing medi-
cations and personal finances.25 Self-rated health 
status was evaluated with a reliable and validated 
single-item measure with responses on a 5-point 
Likert scale which asked: “In general, would you 
say your health is excellent, very good, good, fair, or 
poor?”.26 Participants provided self-reports of hear-
ing and visual impairment, history of falls, whether 
they had experienced AF symptoms in the preced-
ing 4 weeks and health behaviors including alcohol 
use and smoking history (Variables and measures 
assessed in the present study and method of data 
collection are summarized in Table S1).
Statistical Analysis
All the study data were accessible to the lead author 
(H.A.) who takes full responsibility for the integrity of 
the data and accuracy of results obtained from data 
analysis.
In deriving the analytic sample, we excluded par-
ticipants with missing information on the AFEQT QoL 
measure at the 1 year of follow-up contact (n=147). At 
baseline, all participants provided responses to the 
AFEQT measure with no missing data. The analytic 
sample consisted of 1097 of the original 1244-mem-
ber study cohort. Descriptive statistics were used to 
examine participant’s baseline characteristics accord-
ing to whether they experienced a clinically meaningful 
decline, increase, or no clinically meaningful change 
in their QoL between baseline/study enrollment and 
1-year of follow-up. We used independent sample 
t tests to compare differences in mean AFEQT QoL 
scores overall and according to the 3 subscales from 
baseline to 1 year of follow-up.
In examining the factors associated with clini-
cally meaningful change in QoL, ordinal logistic re-
gression models were constructed to calculate the 
crude and multivariable adjusted odds ratios (ORs) 
and accompanying 95% CI. The 3-level outcomes 
were either a clinically meaningful decline, no clini-
cally meaningful change, or clinically meaningful in-
crease in QoL. The proportional odds assumption 
for the ordinal logistic regression models was not 
sufficiently met when evaluated with the Brant test.27 
Thus, we used the partial proportional odds model 
with less restraints on the proportionality assump-
tion.28 Separate regression models were constructed 
to examine factors independently associated with 
clinically meaningful change in the overall AFEQT 
score and the respective subscales: symptoms, daily 
activities, and treatment concerns. We sequentially 
examined patient characteristics and clinical factors 
significantly associated with changes in QoL. Our 
a priori selection of variables was based on clinical 
judgement by identifying those factors assessed in 
our study that may impact patients’ QoL and those 
described in previous studies as being significantly 
associated with QoL among patients with AF. First, 
in univariable models we separately examined the 
association between each variable and clinically 
meaningful change in QoL according to the following 
groups: sociodemographic characteristics (age, sex, 
race/ethnicity, and education), clinical and health be-
havior variables (previously diagnosed comorbidities, 
type of AF, AF symptoms in prior 4 weeks, anticoag-
ulation therapy, rhythm versus rate control therapy, 
risk scores, smoking, and alcohol use), and psy-
chosocial/geriatric measures (symptoms of depres-
sion and anxiety, social support, frailty, self-rated 
health, independent functioning, previous history 
of falls, hearing, visual, and cognitive impairment). 
Subsequently, in each multivariable adjusted model, 
we included only variables that were independently 
associated with a clinically meaningful change in QoL 
from the univariable analysis. Additionally, since the 
baseline QoL score may impact change in QoL over 
time with regression to the mean,29 we adjusted for 
baseline overall QoL score and baseline subscale 
score in the respective univariable and multivariable 




In comparison with included participants (n=1097), the 
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score at 1-year of follow-up were more likely to be of a 
racial/ethnic minority group (12.6% versus 23.1%) and 
a higher proportion reported mild/moderate symp-
toms of depression (24.2% versus 35.4%), had higher 
risk scores (CHA2DS2-VASc, HASBLED, and Charlson 
Comorbidity index), and were more likely to be cogni-
tively impaired (33.2% versus 59.2%) and frail (12.5% 
versus 23.8%) (P<0.05 for all comparisons). The mean 
(SD) score for the overall AFEQT QoL measure at base-
line was significantly higher for those who were in-
cluded in the analytic sample compared with excluded 
participants (80.4 [SD=17.8] versus 77.1 [SD=18.8]; 
P=0.04).
The mean age of study participants (n=1097) was 
75  years, 48% were women, and 87% were White. 
Approximately two thirds had paroxysmal AF, 14% had 
persistent AF, and 18% had permanent AF. There were 
no differences in terms of changes in the QoL scores 
according to type of AF. One third had symptoms of AF 
during the 4 weeks before study enrollment, and 59% 
of patients were on rhythm control (cardioversion or 
ablation therapy). No significant differences were ob-
served in terms of change in QoL scores according to 
whether patients received rhythm versus rate control 
therapy. In addition, symptoms of depression or anx-
iety did not differ according to the type of treatment 
patients received. A majority of patients (95%) were 
prescribed ≥5 medications. There were no differences 
in changes in QoL based on the individual groups of 
commonly prescribed medications. About one quar-
ter of study participants had mild/moderate symptoms 
of depression or mild/moderate symptoms of anxiety 
(Table 1).
Participant QoL at Baseline and 1-Year 
Follow-Up
Among the 1097 study participants, 21.8% had a clini-
cally meaningful decline in their overall AFEQT QoL 
score (≥−5.0 points), 38.0% had no clinically meaning-
ful change in QoL (between −5.0 to +5.0 points), and 
40.2% experienced a clinically meaningful increase in 
their QoL score (≥+5.0 points). The average baseline 
overall AFEQT score was notably low (mean [SD]=69.1 
[18.0]) among those who experienced a clinically mean-
ingful increase in their QoL during follow-up compared 
with those who had a decline (mean [SD]=86.1 [13.1]) or 
no clinically meaningful change (mean [SD]=89.1 [12.6]) 
in their overall QoL (Table 2).
Overall, study participants experienced a 4.3-point 
increase in their mean AFEQT from a baseline score 
of 80.4 to 84.8 at the 1-year follow-up (P<0.001). With 
regards to the 3 QoL subscales, participants reported 
the highest QoL score at baseline on the symptom 
subscale, with a mean of 88.3, and the lowest QoL 
score on the daily activity subscale, with an average 
score of 74.4. Patients had the greatest improvement 
in QoL over 1 year in the daily activity subscale (mean 
change: +5.6) and the least improvement in the symp-
tom subscale (mean change: +1.8) (Table  2). On the 
treatment concern subscale, the average change was 
+4.4 points between baseline and 1 year from an initial 
mean score of 83.1 (19.3) at baseline.
The proportion of participants with a clinically 
meaningful decline in their QoL over 1 year on the daily 
activity, symptom, and treatment concern subscales 
were 25.7%, 20.7%, and 22.0%, respectively (Table 2). 
The proportion of those with a clinically meaningful in-
crease in the daily activity subscale was 40.9% which 
was higher than the values observed on the symptom 
(25.9%) and treatment concern (40.8%) subscales 
(Table 2).
Patient and Clinical Factors Associated 
With Clinically Meaningful Change in QoL
In the multivariable adjusted model examining factors 
associated with clinically meaningful change in over-
all QoL, patients with symptoms of mild/moderate 
depression and fair/poor self-rated health were more 
likely to experience a clinically meaningful decline ver-
sus no clinically meaningful change or clinically mean-
ingful increase in their overall QoL scores than patients 
without symptoms of depression or those who rated 
their health as good/excellent, respectively (Table  3). 
With regards to the symptom’s subscale, those who 
self-reported their health as being fair/poor versus 
good/excellent, and women compared with men, 
were more likely to experience a clinically meaningful 
decline versus no clinically meaningful change or clini-
cally meaningful increase in their QoL (Table 4). On the 
daily activities’ subscale, participants with a prior di-
agnosis of diabetes mellitus or heart failure, and those 
taking ≥5 medications (polypharmacy), were more 
likely to experience clinically meaningful decline in their 
QoL (Table 5). With regards to the treatment concerns 
subscale, patients who were non-Whites compared 
with White, those who reported symptoms of mild/
moderate depression versus none, or moderate anxi-
ety versus none, or those with low social support were 
more likely to experience a clinically meaningful decline 
in their QoL (Table  6). In the overall QoL regression 
models, and the respective subscale models, higher 
baseline QoL scores were associated with clinically 
meaningful decline over the 1-year period of follow-up.
DISCUSSION
In this large prospective study, we described the ex-
tent of clinically meaningful change in QoL, and factors 
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Table 1. Baseline Characteristics of Study Participants According to Clinically Meaningful Changes in QOL From 






Decline in QoL* 
(n=239)
No Clinically Meaningful 
Change in QoL† 
(n=417)
Clinically Meaningful 
Increase in QoL‡ 
(n=441)
Socio-demographic
Age (y, mean [SD]) 75.2 (7.0) 75.6 (7.1) 75.1 (7.0) 75.0 (7.2)
Age categories, %
65–74 y 52.0 51.5 53.7 50.6
75–84 y 36.1 33.0 35.5 38.3
≥85 y 11.9 15.5 10.8 11.1
Women, % 48.3 50.6 42.2 52.8
Race/Ethnicity, %
White 87.4 82.8 88.7 88.6
Non-White 12.6 17.2 11.3 11.4
Married, % 57.4 55.5 60.4 55.5
Education
≤ High school 36.4 41.8 33.3 36.4
Some college 19.4 19.0 16.8 22.1
College graduate 44.2 39.2 49.9 41.5
Clinical
AF type, %
Paroxysmal 67.7 71.1 66.2 67.3
Persistent 14.4 15.6 13.4 14.6
Permanent 17.9 13.3 20.4 18.1
Time since AF diagnosis, (y, mean [SD]) 5.3 (4.3) 5.3 (4.2) 5.5 (4.0) 5.2 (4.5)
Symptoms of AF in past 4 wk, % 29.4 27.4 22.3 37.4
Anticoagulation therapy, %
DOAC 37.1 39.3 31.7 41.0
Warfarin 48.6 47.3 50.8 47.2
None 14.3 13.4 17.5 11.8
AF treatment approach, %
Rhythm control therapy 58.5 61.5 56.3 59.0
Rate control therapy 41.5 38.5 43.7 41.0
Polypharmacy (≥5 medications), % 95.3 97.1 95.2 94.6
Commonly prescribed medications, %
ACE-inhibitors 33.8 32.6 36.4 32.0
ARBs 23.0 23.8 22.1 23.4
Beta-blockers 79.1 80.1 80.4 77.3
Calcium channel blockers 31.4 35.6 28.1 32.4
Digoxin 3.0 2.6 2.5 3.7
Diuretics 50.0 51.9 45.1 52.8
Statins 68.2 70.7 68.1 66.9
CHA2DS2-VASc >2, % 88.3 90.0 85.1 90.5
HASBLED ≥3, % 73.2 73.2 70.0 76.2
Charlson comorbidity index, (mean, SD) 5.9 (2.5) 6.2 (2.5) 5.8 (2.5) 5.9 (2.5)
Medical history, %
Hypertension 89.8 94.6 88.0 88.9
Dyslipidemia 80.2 77.8 80.8 81.0
Diabetes mellitus 29.9 36.0 25.2 31.1
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over 1-year of follow-up among patients ≥65 years with 
AF. Approximately 40% of patients experienced a clini-
cally meaningful increase in their overall QoL whereas 
20% experienced a clinically meaningful decline in their 
overall QoL. Factors independently associated with 






Decline in QoL* 
(n=239)
No Clinically Meaningful 
Change in QoL† 
(n=417)
Clinically Meaningful 
Increase in QoL‡ 
(n=441)
Arthritis 50.4 51.5 47.2 52.8
Anemia 30.6 29.3 28.3 33.6
Cancer 31.0 32.2 33.6 27.9
Psychosocial and geriatric
Depressive symptoms§, %
None 73.2 73.2 80.8 66.0
Mild/moderate 24.3 25.5 18.2 29.2
Moderately severe/severe 2.5 1.3 1.0 4.8
Anxiety symptoms ‖ , %
None 76.9 75.7 84.7 70.1
Mild/moderate 21.4 23.4 14.6 20.8
Severe 1.7 0.9 0.7 3.2
Low social support, % 26.3 27.6 24.5 27.4
Cognitive impairment, % 33.2 38.8 30.9 32.4
Hearing impairment, % 35.5 33.9 32.4 39.5
Visual impairment, % 33.2 34.3 27.8 37.6
Previous history of fall, % 21.4 20.9 18.0 24.8
Frailty, %
Not frail 34.6 32.6 44.4 26.5
Pre-frail 52.9 55.7 48.4 17.9
Frail 12.5 11.7 7.2 55.6
Self-rated health, %
Fair/poor 15.4 16.4 10.1 19.9
Good/excellent 84.6 83.6 89.9 80.1
Independent functioning (IADLs) (mean, SD) 6.8 (0.8) 6.8 (0.8) 6.8 (0.8) 6.7 (1.0)
Baseline overall AFEQT score (mean, SD) 80.4 (17.8) 86.1 (13.1) 89.1 (12.6) 69.1 (18.0)
Health behaviors
Alcohol use, % 57.0 53.2 62.9 53.5
Smoking status, %
Never smoker 46.8 44.9 44.9 49.7
Former smoker 50.1 51.7 52.7 46.9
Current smoker 3.1 3.4 2.4 3.4
Study sites
Georgia, % 22.3 26.4 18.9 23.5
Massachusetts, % 77.7 73.6 81.1 76.5
ACE indicates angiotensin-converting enzymes; AFEQT, Atrial Fibrillation Effect Quality-of-Life; ARBs, Angiotensin Receptor Blockers; CHA2DS2-VASc, 
Congestive heart failure, Hypertension, Age (≥65=1 point, ≥75=2 points), Diabetes Mellitus, and Prior Stroke/Transient Ischemic Attack (2 points), Vascular 
Disease (peripheral artery disease, previous myocardial infarction, aortic atheroma) and female sex; DOAC, direct oral anticoagulant; HAS-BLED, determines 
1-year risk of major bleeding (Hypertension, Abnormal Renal and Liver Function, Prior Stroke, Prior Bleeding, Labile INR, Elderly, Drugs or Alcohol; IADLs, 
Instrumental Activities of Daily Living (score ranging from 0 to 7; INR, International Normalized Ratio; QoL, quality of life; and SAGE-AF, Systematic Assessment 
of Geriatric Elements in Atrial Fibrillation.
*Clinically meaningful decline in quality of life based on Atrial Fibrillation Effect on Quality of Life score at year 1—baseline score ≤−5.0.
†No clinically meaningful change in QoL based on Atrial Fibrillation Effect on Quality of Life score at year 1—baseline score −5.0 to +5.0.
‡Clinically meaningful increase in QoL based on Atrial Fibrillation Effect on Quality of Life score at year 1—baseline score ≥+5.0.
§Patient Health Questionnaire 9-item score (5–9 mild; 10–14 moderate; 15–19 moderately severe; and ≥20 severe depression).
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QoL or at least 1 of its subscales included several pa-
tient sociodemographic and psychosocial characteris-
tics, the presence of previously diagnosed comorbid 
conditions, polypharmacy, and higher baseline QoL 
scores.
Consistent with findings from the few existing 
studies of older patients with AF in the outpatient set-
ting,12,13 most of our study participants did not experi-
ence a major deterioration in their overall QoL during 
the 1-year follow-up period. We postulate that since 
our study participants were recruited from cardiology, 
electrophysiology, and primary care outpatient clin-
ics as opposed to the hospital in-patient setting, they 
may have been relatively stable with greater functional 
status and overall well-being as reflected by their high 
baseline overall QoL score (mean=80.4), and may have 
adapted to their chronic illness, thus being less likely to 
report a deterioration in their QoL.
In the present study, sociodemographic charac-
teristics including sex and race were independently 
associated with change in QoL. Women were more 
likely to experience a clinically meaningful decline in 
their QoL as assessed by the symptom subscale than 
men. Similarly, prior studies that have examined the 
association between sex and baseline QoL in patients 
with AF30–32 and coronary heart disease33,34 have 
shown that women have greater impairment in their 
QoL than men. Perception of one’s symptoms, thresh-
old for reporting AF symptoms, and the presence of 
psychosocial or comorbid factors have been identified 
as plausible reasons for observed sex differences in 
QoL.35 Our prospective findings suggest that not only 












Decline in QoL (%)*
Proportion With No 
Clinically Meaningful 
Change in QoL (%)†
Proportion With 
Clinically Meaningful 
Increase in QoL (%)‡
Overall 80.4 (17.8) 84.8 (15.3) +4.3 <0.001 21.8 38.0 40.2
Symptoms 88.3 (17.5) 90.2 (14.7) +1.8 0.001 20.7 53.4 25.9
Daily activities 74.4 (24.5) 80.0 (21.6) +5.6 <0.001 25.7 33.4 40.9
Treatment 
concern
83.1 (19.3) 87.6 (16.5) +4.4 <0.001 22.0 37.2 40.8
AFEQT indicates Atrial Fibrillation Effect on Quality of Life questionnaire; QoL, quality of life; and SAGE-AF, Systematic Assessment of Geriatric Elements in 
Atrial Fibrillation.
*Clinically meaningful decline in quality of life based on Atrial Fibrillation Effect on Quality of Life score at year 1—baseline score ≤−5.0.
†No clinically meaningful change in quality of life based on Atrial Fibrillation Effect on Quality of Life score at year 1—baseline score <+5.0 to −5.0.
‡Clinically meaningful increase in quality of life based on Atrial Fibrillation Effect on Quality of Life score at year 1—baseline score ≥+5.0.
Table 3. Factors Independently Associated With Clinically 
Meaningful Change (“Decline” vs “No Clinically Meaningful 
Change” or “Increase”) in Overall AFEQT QoL Scores 






Race (non-White vs White) 1.80 (1.25–2.59) 1.46 (0.98–2.16)
Diabetes mellitus 1.43 (1.10–1.86) 1.16 (0.87–1.54)
Hypertension 1.60 (1.08–2.36) 1.33 (0.89–1.98)
Heart Failure 1.42 (1.10–1.83) 1.27 (0.97–1.66)
Visual impairment 1.37 (1.05–1.78) 1.12 (0.84–1.48)
Cognitive impairment 0.75 (0.58–0.97) 0.93 (0.71–1.22)
Polypharmacy 1.85 (1.05–3.27) 1.68 (0.94–2.99)
Fair/poor vs good/excellent 
self-rated health
2.08 (1.43–3.01) 1.57 (1.05–2.35)†
Mild Anxiety vs none 1.71 (1.23–2.39) 1.44 (0.99–2.08)
Mild/moderate depression 
vs none
1.92 (1.40–2.62) 1.62 (1.14–2.31)†
AFEQT indicates Atrial Fibrillation Effect on Quality of Life; OR, odds 
ratio; QoL, quality of life; and SAGE-AF, Systematic Assessment of Geriatric 
Elements in Atrial Fibrillation study.
*Adjusted model includes only variables associated with change in QoL 
in the univariable models and the overall baseline Atrial Fibrillation Effect on 
Quality of Life score.
†Statistically significant results.
Table 4. Factors Independently Associated With Clinically 
Meaningful Change (“Decline” vs “No Clinically Meaningful 
Change” or “Increase”) in AFEQT Symptom Subscale 






Sex (women vs men) 1.60 (1.24–2.06) 1.45 (1.10–1.91)†
Marital status (married vs not 
married)
0.73 (0.57–0.95) 0.87 (0.66–1.15)
Cognitive impairment 0.72 (0.55–0.94) 0.80 (0.60–1.06)
Vision impairment 1.40 (1.06–1.83) 1.11 (0.83–1.49)
Mild/moderate depression 
vs none
2.25 (1.56–3.23) 1.00 (0.64–1.56)
Mild anxiety vs none 1.59 (1.13–2.24) 1.28 (0.47–1.87)
Moderate anxiety vs none 3.06 (1.38–6.77) 1.91 (0.82–4.41)
Independent activities of daily 
living
0.85 (0.74–0.97) 0.97 (0.79–1.20)
Fair/poor vs good/excellent 
self-rated health
2.00 (1.40–2.86) 1.64 (1.12–2.42)†
AFEQT indicates Atrial Fibrillation Effect on Quality of Life; OR, odds 
ratio; and SAGE-AF, Systematic Assessment of Geriatric Elements in Atrial 
Fibrillation study.
*Adjusted model includes only variables associated with change in quality 
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do women have poorer QoL than men at a given point 
in time, but that they may be more likely to experience 
deterioration in their QoL over the course of their ill-
ness as compared with men. These data suggest that 
during routine follow-up visits, healthcare providers 
should regularly assess how women’s experience of 
their AF symptoms may negatively impact their overall 
well-being and functional status.
Study participants from racial/ethnic minority 
groups were more likely to experience clinically mean-
ingful decline in their QoL on the treatment concern 
subscale compared with Whites. There has been lim-
ited study of racial disparities in QoL among patients 
with AF. Recent findings from the ORBIT-AF registry 
of 9542 American adults with incident and prevalent 
AF, showed that Black individuals, who comprised only 
5% of their study population, had a higher symptom 
burden of AF and lower QoL at baseline and 2 years 
of follow-up in comparison with Whites.36 Reports 
from various clinical and epidemiological studies have 
consistently shown a lower incidence and prevalence 
of AF in racial/ethnic minority groups.37,38 To enhance 
our understanding of patient-centered outcomes in 
racial/ethnic minority groups with AF, implementing 
targeted strategies for recruiting and retaining more 
minorities in population-based studies and clinical tri-
als may enhance our understanding of racial variations 
in treatment strategies, QoL changes, and long-term 
health outcomes.39
We observed that several psychosocial factors, 
such as symptoms of depression, anxiety, and fair/
poor self-rated health were independently associated 
with clinically meaningful change in QoL. Patients with 
symptoms of mild/moderate depression and those 
who rated their health as fair/poor were more likely to 
experience decline in their overall QoL over the 1-year 
follow-up period. Similarly, those who rated their health 
as fair/poor as opposed to good/excellent experienced 
a clinically meaningful decline versus an increase or no 
clinically meaningful change on the symptom QoL sub-
scale. Participants with symptoms of mild/moderate 
depression and those with mild anxiety experienced 
declining QoL on the treatment concern subscale. 
Prior studies conducted in patients with AF have re-
ported an association between symptoms of depres-
sion, anxiety, poorly perceived health status, stress, 
and impaired QoL.40–42 In a cross-sectional study 
among 207 patients recruited from an outpatient ar-
rhythmia clinic and those hospitalized in a cardiac pro-
gressive care unit, poor illness perception of AF such 
as attributing serious consequences to AF and a lack 
Table 5. Factors Independently Associated With Clinically 
Meaningful Change (“Decline” vs “No Clinically Meaningful 
Change” or “Increase”) in AFEQT Daily Activity Subscale 






Race (non-White vs White) 1.44 (1.01–2.07) 1.14 (0.76–1.73)
Type of AF (persistent vs 
paroxysmal)
1.45 (1.01–2.07) 1.44 (0.99–2.09)
Diabetes mellitus 1.74 (1.34–2.26) 1.45 (1.07–1.96)†
Hypertension 1.68 (1.13–2.50) 1.27 (0.82–1.97)
Heart failure 1.67 (1.29–2.16) 1.33 (1.00–1.78)†
Cognitive impairment 0.73 (0.57–0.94) 0.84 (0.63–1.12)
Vision impairment 1.43 (1.10–1.85) 1.14 (0.86–1.52)
Mild/moderate depression 
vs none
1.77 (1.24–2.51) 1.30 (0.93–1.81)
Pre-frail vs not frail 1.30 (1.00–1.67) 1.30 (0.94–1.79)
Frail vs not frail 2.05 (1.31–3.19) 1.27 (0.76–2.11)
Polypharmacy 2.21 (1.26–3.88) 1.80 (1.00–3.21)†
BMI (≥30 kg/m2 vs <25 kg/m2) 1.46 (1.05–2.02) 1.25 (0.87–1.79)
Fair/poor self-rated health vs 
good/excellent
2.22 (1.48–3.33) 1.32 (0.87–2.02)
AF indicates atrial fibrillation; AFEQT, Atrial Fibrillation Effect on Quality 
of Life; BMI, body mass index; OR, odds ratio; and SAGE-AF, Systematic 
Assessment of Geriatric Elements in Atrial Fibrillation study.
*Adjusted model includes only variables associated with change in quality 
of life in the univariable models and baseline daily activity subscale score.
†Statistically significant results.
Table 6. Factors Independently Associated With Clinically 
Meaningful Change (“Decline” vs “No Clinically Meaningful 
Change” or “Increase”) in AFEQT Treatment Concern 






Race/Ethnicity (non-White vs 
White)
2.26 (1.57–3.27) 1.63 (1.09–2.45)†
Some College vs ≤ High 
School
0.67 (0.47–0.94) 0.78 (0.55–1.12)
College Graduate vs ≤ High 
School
0.70 (0.54–0.92) 0.88 (0.66–1.18)
Diabetes mellitus 1.51 (1.16–1.97) 1.30 (0.98–1.73)
Mild/moderate depression vs  
none
2.08 (1.52–2.84) 1.63 (1.13–2.33)†
Mild anxiety vs none 2.15 (1.50–3.06) 1.77 (1.20–2.61)†
Moderate anxiety vs none 2.18 (1.07–4.46) 1.50 (0.68–3.27)
Fair/poor self-rated health vs 
good/excellent
1.97 (1.37–2.85) 1.46 (0.97–2.21)
Pre-frail vs not frail 1.34 (1.03–1.73) 1.07 (0.81–1.40)
Frail vs not frail 1.77 (1.11–2.81) 0.99 (0.59–1.67)
Visual impairment 1.56 (1.20–2.03) 1.22 (0.92–1.62)
Cognitive impairment 0.68 (0.53–0.88) 0.86 (0.65–1.15)
Low social support 1.54 (1.17–2.03) 1.47 (1.11–1.94)†
AFEQT indicates Atrial Fibrillation Effect on Quality of Life; OR, odds 
ratio; and SAGE-AF, Systematic Assessment of Geriatric Elements in Atrial 
Fibrillation study.
*Adjusted model includes only variables associated with change in quality 
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of understanding of their AF condition was associated 
with greater psychological distress, anxiety, and de-
pression.43 Our findings further highlight an important 
temporal relationship between symptoms of depres-
sion or fair/poor self-rated health at baseline and an in-
creased risk of experiencing declines in QoL over time. 
Living and coping on a daily basis with symptoms of 
AF, depression, and/or anxiety, as well as perceiving 
one’s health to be fair/poor may be particularly burden-
some for patients from the perspective of disordered 
mind-body interactions,44 which may lead to deterio-
ration in one’s perception of their overall well-being. 
These findings reinforce the need for early assess-
ment of patient’s psychological well-being including 
symptoms of depression, anxiety, and self-reports of 
their health status, which provides an opportunity to 
institute treatment strategies that may be pivotal in im-
proving patient’s psychological symptoms, QoL, and 
could ultimately impact their response to AF treatment. 
In addition, we recommend improved approaches for 
clinical practice with standardized screening of self-
rated health, depression, and anxiety in high-risk older 
patients with AF.
Furthermore, reports of low social support among 
our study participants were associated with a decline 
in QoL as assessed by the treatment concerns sub-
scale. Our finding is in keeping with those from pre-
vious studies that emphasize the important role of 
caregivers in periods of illness or having a strong sup-
port system which fosters well-being and QoL.45,46 For 
a more holistic approach to patient care, addressing 
the social determinants of health, including access to 
care, transportation, safe environment, and availability 
of caregiver support may help identify patients with low 
social support and those in need of referral for social 
workers intervention and assistance.
The presence of a number of comorbid conditions, 
most notably heart failure and diabetes mellitus, and the 
use of ≥5 medications (polypharmacy) at baseline were 
associated with clinically meaningful decline in QoL as-
sessed on the daily activity subscale. Our study partici-
pants were older men and women with a high burden of 
several comorbid conditions which have been identified 
as risk factors for the development of AF.47,48 Previous 
studies have shown an association between comorbid-
ities and poor QoL in patients with AF.6,9 Our obser-
vation that the presence of several comorbid diseases 
was associated with greater decline in QoL over 1-year 
of follow-up further emphasizes that older patients with 
AF who have coexisting cardiometabolic diseases may 
have reduced physical reserve and experience increas-
ingly worsening AF symptoms over the period of their 
illness.6 Furthermore, the high proportion of study par-
ticipants who were prescribed ≥5 medications is reflec-
tive of the considerable burden of comorbidities among 
this cohort of patients. The burden of ingesting multiple 
pills for co-existing medical conditions and dealing with 
potential side effects of these medications may be over-
whelming and could negatively impact patients’ QoL. 
These results and those from prior studies buttress the 
need for a more holistic approach in patient manage-
ment to address the presence of comorbid conditions 
while simultaneously providing rate/rhythm control in 
patients with AF for sustained improvement in QoL and 
overall well-being.
An important goal of AF management is symp-
tom improvement through rate or rhythm control.5 
Interestingly, we observed that during the 1-year pe-
riod of follow-up, study participants experienced the 
greatest improvement in their QoL on the daily activ-
ity subscale reporting that they were able to function 
more optimally while carrying out their daily activities 
and spending time with their loved ones as opposed 
to alleviation of their cardiac related symptoms. This 
finding suggests the need for a better understanding 
of those aspects of one’s illness experience that mat-
ter most to patients as they undergo treatment for AF. 
However, we recognize that there may have been a po-
tential ceiling effect, since the symptom subscale had 
the highest mean score at the time of baseline study 
enrollment with less likelihood for improvement com-
pared with the daily activity subscale which had the 
lowest mean value at baseline.
Although previous research has shown that treat-
ment approaches to restoring sinus rhythm are associ-
ated with improvement in QoL,49,50 we did not observe 
any significant association between rate or rhythm 
control strategies and clinically meaningful changes in 
overall QoL over our 1-year period of follow-up. Future 
longitudinal studies should examine the impact of rate 
or rhythm control on clinically meaningful changes in 
QoL over longer periods of follow-up to better evaluate 
if there are sustained effects of various treatment ap-
proaches on patient-reported outcomes including their 
QoL.
Study Strengths and Limitations
To the best of our knowledge, this is the first contem-
porary inquiry into the factors associated with clinically 
meaningful change in QoL among a well characterized 
cohort of older men and women diagnosed with AF 
with a detailed assessment of their clinical, psychoso-
cial, and geriatric characteristics. In addition, the AFEQT 
questionnaire used to assess the impact of AF on QoL 
among our study participants is a well-established 
and widely accepted measure, enhancing the valid-
ity and reproducibility of our study findings. However, 
our results should be interpreted in the light of several 
limitations. We recognize that a majority of our study 
participants were recruited from study sites only in the 
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States which could lead to potential selection bias and 
limited generalizability of our results to more ethnically 
diverse populations. We acknowledge that the assess-
ment of QoL among our study participants is entirely 
subjective and may be influenced by one’s personal 
illness experience and their cultural beliefs and val-
ues, which may limit the generalizability of our study 
findings to sicker populations diagnosed with AF and 
those of varying socio-cultural groups. In addition, the 
cut point used for defining clinically meaningful decline 
in QoL may not be applicable in different patient popu-
lations with AF. Given our observational study design, 
there may be unmeasured factors that could impact 
clinically meaningful changes in patients QoL which 
were not accounted for in our study and potentially 
bias our effect estimates. Future longitudinal studies 
should use a multi-stake holder approach to directly 
assess the factors that may influence change in QoL 
from both the perspective of patients, their caregivers, 
and healthcare providers. These studies should also 
conduct multiple assessments of QoL during longer 
follow-up periods to identify particularly high-risk pe-
riods where interventions may be most beneficial and 
enhance the depth of our understanding of long-term 
changes in QoL while managing men and women from 
different age groups diagnosed with AF.
CONCLUSIONS
In this large multicenter prospective study among 
older adults with AF, we observed that ≈2 in every 5 
patients experienced clinically meaningful increases 
in their QoL over 1 year of follow-up and 1 in 5 pa-
tients had a clinically meaningful decline in their over-
all QoL. Female participants reported mild/moderate 
symptoms of depression and anxiety, fair/poor self-
rated health, had lower social support, and those 
with previously diagnosed comorbidities and poly-
pharmacy were more likely to experience clinically 
meaningful decline in their overall QoL and on the 
symptom, daily activities, and treatment subscales. 
Our study provides timely and clinically relevant in-
formation for healthcare providers to assess potential 
factors that may lead to a progressive decline in QoL 
among patients with AF, and further reinforces the 
need for a more holistic approach in patient man-
agement to improve the functional status and overall 
well-being of older men and women with AF.
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Table S1. Variables assessed in the present SAGE-AF Study. 




Outcome Measure    
Quality of Life (Atrial Fibrillation Effect Quality-of-Life (AFEQT) 
Questionnaire [16] 
✓   
   
Sociodemographic characteristics    
Age   ✓  
Sex   ✓  
Race/ethnicity ✓   
Level of Education  ✓   
Marital status  ✓   
   
Clinical variables    
Type of AF  ✓  
Time since AF diagnosis   ✓  
Symptoms of AF in past 4 weeks  ✓   
Anticoagulation therapy  ✓  
AF treatment approach   ✓  
Medication use   ✓  
Medical history  ✓  
   
Psychosocial and Geriatric characteristics    
Social Support (Medical Outcomes Social Support Survey) [19] ✓   
Cognitive Assessment (Montreal Cognitive Assessment Battery 
(MoCA)) [20, 21] 
✓   
Frailty (Cardiovascular Health Survey (CHS) frailty scale) [22] ✓   
Symptoms of Depression (PHQ-9) [23] ✓   
Symptoms of Anxiety (GAD-7) [24] ✓   
Independent functioning (Instrumental activities of daily living) [25] ✓   
Self-Rated Health [26] ✓   
Self-reported hearing impairment  ✓   
Self-reported visual impairment  ✓   
History of Fall  ✓   
   
Health Behaviors    
Alcohol use  ✓   
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